May 6, 2011, Saint Louis Business Journal
Local biotech startup C2N Diagnostics LLC is leading the way in finding new, more effective treatments for Alzheimer’s disease and other disorders through a unique metabolic labeling technology.
The technology, stable isotope-linked kinetics (SILK), was discovered at Washington University School of Medicine by Drs. Randall Bateman and David Holtzman. The technique allows tracking of the brain’s production and clearance of amyloid beta, a protein that’s closely linked to the disease. This gives scientists insights into the progression of the disease and enables physicians to start an effective course of treatment before the patient exhibits clinical symptoms.